報價延遲最少15分鐘:2026/11/04 13:18 EST
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.8836 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.75/-0.96
|
|
企業價值
119.06M
|
| 資產負債 |
|
每股賬面淨值
1.67
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
70.00M
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding ofcancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor,is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment. |
